Literature DB >> 12508973

Hyperbaric oxygen therapy in two patients with non-arteritic anterior optic neuropathy who did not respond to prednisone.

L Bojić1, M Ivanisević, G Gosović.   

Abstract

Recent advances in understanding the effects of hyperbaric oxygen (HBO) on retinal anoxia gave rise to new interest in the possibility of using it as therapeutic treatment for ischemic conditions of the retina and optic nerve. Two patients with non-arteritic anterior ischemic optic neuropathy due to a high-grade ophthalmic artery stenosis were treated with HBO at 2 atm abs in an effort to increase oxygen delivery for the eye. Both patients showed marked improvements of visual acuity and visual field 3-5 months following the event. Our results are intriguing although the achieved improvement could be coincidental.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12508973

Source DB:  PubMed          Journal:  Undersea Hyperb Med        ISSN: 1066-2936            Impact factor:   0.698


  4 in total

1.  Slowing the degenerative process, long lasting effect of hyperbaric oxygen therapy in retinitis pigmentosa.

Authors:  Enzo Maria Vingolo; Monica Rocco; PierLuigi Grenga; Serena Salvatore; Paolo Pelaia
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-03       Impact factor: 3.117

Review 2.  Purtscher-like retinopathy - A rare complication of acute myocardial infarction and a review of the literature.

Authors:  Leslie Jonathan Pek Seng Ang; Benjamin Chong Ming Chang
Journal:  Saudi J Ophthalmol       Date:  2017-05-22

3.  Efficacy of Hyperbaric Oxygen Therapy on Central Corneal Thickness, Intraocular Pressure, and Nerve Fiber Layer in Patients with Type 2 Diabetes: A Prospective Cohort Study.

Authors:  Havva Kaldırım; Kürsat Atalay; Banu Ceylan; Serpil Yazgan
Journal:  Korean J Ophthalmol       Date:  2020-12-11

4.  Acute Effect of Hypervolemic Hemodilution on Retrobulbar Hemodynamics in Anterior Ischemic Optic Neuropathy.

Authors:  Marion Bienert; Niklas Plange; Andreas Remky; Kay Oliver Arend; David Kuerten
Journal:  Biomed Res Int       Date:  2018-02-06       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.